Hims & Hers Stock Gains After FDA Panel Recommends Wider Access for BPC-157 Peptide

Shares of Hims & Hers Health, Inc. (NYSE: HIMS) rose sharply on Tuesday after a U.S. Food and Drug Administration (FDA) advisory panel narrowly recommended expanding consumer access to the peptide BPC-157. The development was viewed favorably by the market, given the telehealth company's focus on wellness and prescription products.

Panel Delivers Narrow Recommendation

According to a report from Investing.com, the stock climbed 7.9% following the announcement. The move was a direct reaction to the FDA advisory committee's vote on the compound.

Key details from the vote include:

• A final tally of 8-to-6 in favor of the recommendation.
• One committee member abstained from the vote.

Ad

The outcome represents a potentially positive step for companies like Hims & Hers that operate in the health and wellness space and could offer products containing the peptide.

A Non-Binding but Important Step

It is crucial for investors to understand that recommendations from FDA advisory committees are non-binding. The FDA will consider the panel's input but is not obligated to follow its guidance when making a final regulatory decision.

The close vote margin suggests a significant division of opinion among the experts on the panel regarding the peptide's safety and efficacy for wider availability. The FDA will now weigh this divided recommendation as it determines the final regulatory pathway for BPC-157.